Cite
HARVARD Citation
Chow, S. et al. (n.d.). High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection. Journal for immunotherapy of cancer. p. . [Online].